ClinVar Miner

Submissions for variant NM_003000.2(SDHB):c.725G>A (p.Arg242His) (rs74315368)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129095 SCV000183806 pathogenic Hereditary cancer-predisposing syndrome 2019-01-14 criteria provided, single submitter clinical testing The p.R242H pathogenic mutation (also known as c.725G>A), located in coding exon 7 of the SDHB gene, results from a G to A substitution at nucleotide position 725. The arginine at codon 242 is replaced by histidine, an amino acid with highly similar properties. The p.R242H mutation has been well described in published literature. It has been identified in numerous individuals with tumors across the paraganglioma-pheochromocytoma (PGL-PCC) syndrome spectrum, including thoracic, pelvic, and head and neck PGL, adrenal PCC, and renal cell carcinoma (Neumann HP et al. JAMA. 2004 Aug;292:943-51; Ghayee HK et al. Endocr. Relat. Cancer. 2009 Mar;16:291-9; Luiz HV et al. Pediatrics. 2013 Dec;32:e1709-14; Persu A et al. J. Hypertens. 2008 Jul;26:1395-401; Burnichon N et al. J. Clin. Endocrinol. Metab. 2009 Aug;94:2817-27; Merlo A et al. J. Clin. Endocrinol. Metab 2013 Oct;98:E1661-6; Rattenberry E et al. J. Clin. Endocrinol. Metab. 2013 Jul;98:E1248-56; van Hulsteijn LT et al. Fam. Cancer. 2014 Dec;13:651-7; Janssen I et al. Clin. Cancer Res. 2015 Sep;21:3888-95; Gill AJ et al. Am. J. Surg. Pathol. 2014 Dec;38:1588-602). In one study, mutant yeast strains with this mutation showed a significant defect and structural analysis suggested that this mutation alters the conformation of the protein, causing a decrease in the positive surface extent of the mutant protein (Nesti C et al. Hum. Mol. Genet. 2015 Jun;24:3248-56). Additionally, structural modeling of this mutation has predicted disruption of the electron path and impaired functional activity (Kim E et al. Endocr. Relat. Cancer. 2015 Jun;22:387-97). Of note, two different alterations at the same codon, p.R242C and p.R242S, have also been reported in patients with head/neck PGLs and PCCs (Panizza E et al. Hum. Mol. Genet. 2013 Feb;22:804-15; Neumann HP et al. Cancer Res. 2009 Apr;69:3650-6; Lefebvre S et al. Horm. Metab. Res. 2012 May;44:334-8; Badenhop RF et al. J. Med. Genet. 2004 Jul;41:e99). Based on the available evidence, this alteration is interpreted as a disease-causing mutation.
GeneDx RCV000183216 SCV000235636 pathogenic not provided 2019-01-09 criteria provided, single submitter clinical testing This pathogenic variant is denoted SDHB c.725G>A at the cDNA level, p.Arg242His (R242H) at the protein level, and results in the change of an Arginine to a Histidine (CGC>CAC). This variant has been reported in a father and son with malignant paragangliomas, several individuals with both malignant and benign paraganglioma/ pheochromocytoma tumors, a young adult with a gastrointestinal stromal tumor, and a patient with an SDHB-deficient renal carcinoma (Young 2002, Neumann 2004, Persu 2008, Cascon 2009, Ghayee 2009, Sevilla 2009, Janeway 2011, Luiz 2013, Gill 2014, Rijken 2017). SDHB Arg242His was also observed in a patient with clinical and metabolic features suggestive of a mitochondrial disorder, for whom assays to interrogate mitochondrial dysfunction in cultured fibroblasts and muscle tissue revealed reduced complex II and III activities and SDHA and SDHB expression (Nesti 2015). While this patient also harbored a heteroplasmic MT-CYB variant which might have contributed to these laboratory findings, yeast-based assays interrogating each variant separately only found decreased complex II and III activities for the strain expressing the yeast corollary of SDHB Arg242His (Nesti 2015). Additionally, Kim et al. (2015) found SDHB Arg242His to significantly reduce SDH activity, while Dwight et al. (2017) demonstrated this variant to completely abrogate SDHAF3 interaction. SDHB Arg242His was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located in an L(I)YR motif required for interaction with Fe-S cluster transfer machinery and acquisition (Maio 2014, Saxena 2015). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, we consider this variant to be pathogenic.
Invitae RCV000627751 SCV000644767 pathogenic Gastrointestinal stromal tumor; Paragangliomas 4; Pheochromocytoma 2020-09-22 criteria provided, single submitter clinical testing This sequence change replaces arginine with histidine at codon 242 of the SDHB protein (p.Arg242His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine. This variant is present in population databases (rs74315368, ExAC 0.01%). This variant has been observed in several individuals and families affected with sporadic and familial hereditary paragangliomas and/or pheochromocytomas (PMID: 12000816, 20208144, 24276837, 12213855, 17102084, 22270996), gastrointestinal stromal tumors (PMID: 21173220), and mitochondrial encephalomyopathy (PMID: 25736212). ClinVar contains an entry for this variant (Variation ID: 12781). Experimental studies using a model organism have shown that this variant causes deleterious effects on several aspects of protein function (PMID: 25972245, 25736212, 22835832). For these reasons, this variant has been classified as Pathogenic.
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV000013619 SCV001367997 pathogenic Paragangliomas 4 2019-04-17 criteria provided, single submitter clinical testing This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PS3,PP3.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000183216 SCV001746833 pathogenic not provided 2021-05-01 criteria provided, single submitter clinical testing
OMIM RCV000013619 SCV000033866 pathogenic Paragangliomas 4 2011-01-04 no assertion criteria provided literature only
OMIM RCV000013620 SCV000033867 pathogenic Pheochromocytoma 2011-01-04 no assertion criteria provided literature only
OMIM RCV000022778 SCV000044067 pathogenic Gastrointestinal stromal tumor 2011-01-04 no assertion criteria provided literature only
Section on Medical Neuroendocrinolgy,National Institutes of Health RCV000505354 SCV000599525 pathogenic Hereditary Paraganglioma-Pheochromocytoma Syndromes no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.